layoffs
Repare Therapeutics Reduces Workforce by 75 Percent
The firm said its remaining employees will focus on developing the pol theta inhibitor RP-3467 and the PLK4 inhibitor RP-1664.
Encoded Therapeutics Lays off 29 Percent of Workforce
The move will provide funds to advance ETX101, a gene therapy the company is developing for SCN1A-positive Dravet syndrome, among other programs.
Viracta Therapeutics Shuts Down Operations, Lays off All Staff
The company is still seeking strategic options for its development programs, including nana-val, which it was testing in EBV-positive refractory lymphoma.
Fractyl Health Expects to Launch Clinical Trial of Type 2 Diabetes Gene Therapy in 2025
While the company is prioritizing RJVA-001 and a lead program in obesity, it's pausing some R&D efforts and laying off 17 percent of its workforce.
Cargo Therapeutics Nixes Phase II CAR T-Cell Study, Cuts Workforce by 50 Percent
The changes will extend the company's cash runway, enabling it to advance a tri-specific CAR T-cell candidate and its allogeneic cell therapy platform.
Jan 15, 2025
Apr 25, 2024